AU2001286727A1 - Prodrugs activated by plasmin and their use in cancer chemotherapy - Google Patents

Prodrugs activated by plasmin and their use in cancer chemotherapy

Info

Publication number
AU2001286727A1
AU2001286727A1 AU2001286727A AU8672701A AU2001286727A1 AU 2001286727 A1 AU2001286727 A1 AU 2001286727A1 AU 2001286727 A AU2001286727 A AU 2001286727A AU 8672701 A AU8672701 A AU 8672701A AU 2001286727 A1 AU2001286727 A1 AU 2001286727A1
Authority
AU
Australia
Prior art keywords
plasmin
cancer chemotherapy
prodrugs activated
prodrugs
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286727A
Inventor
Vincent Dubois
Alexandre Passioukov
Andre Trouet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coulter Pharmaceutical Inc
Original Assignee
Coulter Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coulter Pharmaceutical Inc filed Critical Coulter Pharmaceutical Inc
Publication of AU2001286727A1 publication Critical patent/AU2001286727A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
AU2001286727A 2000-08-24 2001-08-23 Prodrugs activated by plasmin and their use in cancer chemotherapy Abandoned AU2001286727A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22768600P 2000-08-24 2000-08-24
US60227686 2000-08-24
PCT/US2001/026476 WO2002015700A1 (en) 2000-08-24 2001-08-23 Prodrugs activated by plasmin and their use in cancer chemotherapy

Publications (1)

Publication Number Publication Date
AU2001286727A1 true AU2001286727A1 (en) 2002-03-04

Family

ID=22854074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286727A Abandoned AU2001286727A1 (en) 2000-08-24 2001-08-23 Prodrugs activated by plasmin and their use in cancer chemotherapy

Country Status (3)

Country Link
US (2) US7402556B2 (en)
AU (1) AU2001286727A1 (en)
WO (1) WO2002015700A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097586A1 (en) * 2001-01-30 2004-05-20 Andre Trouet Anti-tumor compounds
NZ529788A (en) 2001-05-31 2003-12-19 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
ES2325495T3 (en) * 2002-07-08 2009-09-07 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. HYBRID MOLECULES OF MACROLIDS WITH STEROID AND NON-STEROID ANTI-INFLAMMATORY MOLECULES.
CA2489398A1 (en) 2002-07-08 2004-01-15 Pliva-Istrazivacki Institut D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
FR2847268B1 (en) * 2002-11-19 2006-09-29 Coletica METHOD FOR IDENTIFYING AN EVENTUALLY MODIFICATION OF AT LEAST ONE BIOLOGICAL PARAMETER USING LIVING CELLS SUBJECT TO STRESS AND LIVING CELLS NOT SUBJECT TO THIS SAME STRESS
TWI412367B (en) 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
KR20090122439A (en) 2007-02-21 2009-11-30 메다렉스, 인코포레이티드 Chemical linkers with single amino acids and conjugates thereof
PL2842575T3 (en) 2008-03-18 2018-02-28 Seattle Genetics, Inc. Auristatin drug linker conjugates
US9005577B2 (en) 2008-04-30 2015-04-14 Siemens Medical Solutions Usa, Inc. Substrate based PET imaging agents
US9238878B2 (en) * 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
BR112013017980A2 (en) 2011-01-14 2017-06-27 Redwood Bioscience Inc aldehyde-labeled immunoglobulin polypeptides and method of use
EP2677029B1 (en) * 2011-05-19 2017-05-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
EP2712361A4 (en) 2011-05-20 2015-03-11 Univ Howard Emetine derivatives, prodrugs containing same, and methods of treating conditions using same
MX363788B (en) 2012-11-21 2019-04-03 Ipsen Bioinnovation Ltd Methods for the manufacture of proteolytically processed polypeptides.
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014160037A2 (en) 2013-03-14 2014-10-02 The Regents Of The University Of California Activatable membrane-interacting peptides and methods of use
CN112472699A (en) 2013-07-26 2021-03-12 种族肿瘤学公司 Combination methods for improving the therapeutic benefit of bisantrene and derivatives
EA036949B1 (en) * 2015-05-29 2021-01-19 Эрроухэд Фармасьютикалз, Инк. Biologically cleavable tetrapeptide linking agents
JP2019515677A (en) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー Antibody conjugates and methods of making and using the same
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
JP7023933B2 (en) 2016-08-19 2022-02-22 ブリストル－マイヤーズ スクイブ カンパニー Seco-cyclopropyrroloindole compound, its antibody-drug conjugate, and how to make and use it.
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296105A (en) 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
DE2936543A1 (en) * 1979-09-10 1981-04-09 Behringwerke Ag, 3550 Marburg CHROMOGENIC COMPOUNDS
AU598750B2 (en) * 1985-09-27 1990-07-05 Mitsubishi Chemical Corporation Phenylalanine derivative and proteinase inhibitor
NZ291368A (en) * 1994-08-19 1999-04-29 Wallone Region A compound comprising a marker or a therapeutic agent linked to a ligand containing amino acids wherein the marker or agent is cleaved from the ligand to permit entry into the cell of the marker or agent, medicaments for treating tumours; diagnostic devices
US5659061A (en) * 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
EP1144011B1 (en) * 1998-12-11 2010-03-10 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
EP1515981A4 (en) * 2001-01-31 2005-03-23 Millennium Pharm Inc Novel molecules of the pyrin/nbs/lrr protein family and uses thereof

Also Published As

Publication number Publication date
US20040171562A1 (en) 2004-09-02
US20090076176A1 (en) 2009-03-19
WO2002015700A1 (en) 2002-02-28
US7893023B2 (en) 2011-02-22
US7402556B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
AU2001286727A1 (en) Prodrugs activated by plasmin and their use in cancer chemotherapy
AU2001253140A1 (en) Tumor markers in ovarian cancer
AU3084901A (en) Volume holographic diffusers
MXPA03004644A (en) Phenylacetamido- pyrazole derivatives and their use as antitumor agents.
AU2003293376A1 (en) Anti-angiogenic compounds and their use in cancer treatment
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU2001227122A1 (en) Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
AU2002211717A1 (en) Stresscopins and their uses
AUPQ926600A0 (en) Improvements in fluid delivery systems
GB0002835D0 (en) Drug resistance in cancer
AU2003217421A1 (en) Prostate specific genes and the use thereof in design or therapeutics
AU2001261750A1 (en) Laminate and its use
AU2002362613A1 (en) Galectins-1-and-4 in tumor development
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001258098A1 (en) Ginsenoside chemotherapy
AU2001272655A1 (en) Improvements in valves
AUPQ526100A0 (en) Improvements in single use syringes
GB0028879D0 (en) Adsorbents and their use
AU2001257325A1 (en) Cancer treatment
AU2001268466A1 (en) 55p4h4: gene expressed in various cancers
AU2002223468A1 (en) Dual shower in three designs
AU2001257168A1 (en) Cancer treatment
AU2002223149A1 (en) Anticancer agent comprising mycolactone
AU2001247922A1 (en) Calpain inhibitors in cancer treatment